
    
      A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Midazolam, a
      CYP3A4 Substrate, in Healthy Subjects When Administered Alone and in Combination with a
      Single Dose of 800-mg Vandetanib (CAPRELSA)
    
  